Omid Yousefian, MD
Cardiovascular Disease · Santa Barbara, CANPI 1588041875
Payments from drug & device makers
Across 587 payments — averaging $79.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$19K
- Abbott$11K
- Biosense Webster, Inc.$10K
- Boston Scientific$3K
- Philips North America LLC$2K
- Cook Medical LLC$422
- plus $2K from 21 others
What the payments were for
- Consulting fees$3,1517%
- Grants$1,7274%
- Travel & lodging$15,71734%
- Food & beverage$25,28954%
- Education$6411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 233 | $19,170 |
| Abbott | 93 | $10,504 |
| Biosense Webster, Inc. | 134 | $9,815 |
| Boston Scientific | 51 | $3,181 |
| Philips North America LLC | 11 | $1,565 |
| Cook Medical LLC | 12 | $422 |
| Shockwave Medical, Inc | 1 | $240 |
| Boehringer Ingelheim | 8 | $192 |
| Novartis | 6 | $173 |
| Medical Device Business Services, Inc. | 4 | $138 |
| Amgen | 3 | $126 |
| Pfizer | 5 | $113 |
| Regeneron Healthcare Solutions, Inc. | 1 | $112 |
| Irhythm Technologies, Inc. | 1 | $102 |
| Cordis US CORP. | 1 | $96 |
| Cardiva Medical, Inc. | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Merit Medical Systems Inc | 1 | $74 |
| Abiomed | 1 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $61 |
| Bayer | 2 | $56 |
| Stryker | 2 | $39 |
| AstraZeneca | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Altathera Pharmaceuticals LLC | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$6,166
- AVEIR$4,122
- EnSite Precision Cardiac Mapping System$1,690
- AMPLIA MRI QUAD CRT-D SURESCAN$993
- ENSITE PRECISION$920
- (9124) LM Undivided$830
- Micra$793
- SelectSecure$758
- VersaCross Access Solution$707
- PulseSelect$643
- QDOT MICRO Catheter$638
- S-ICD System Magnet$590
- AFFERA MAPPING SYSTEM$541
- (9520) IGT Devices Undivided$518
- LINQ II$365
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$300
- ARCTIC FRONT ADVANCE$259
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$240
- HeartMate 3 Left Ventricular Assist Device$221
- AMPLATZER PICCOLO$204
How this compares
$46,525 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 211 | $233,043 |
| JardianceEmpagliflozin | 33 | $42,200 |
| EntrestoSacubitril/Valsartan | 33 | $39,928 |
| XareltoRivaroxaban | 25 | $31,337 |
| Repatha SureclickEvolocumab | 21 | $20,503 |
| VascepaIcosapent Ethyl | 21 | $12,512 |
| Praluent PenAlirocumab | 11 | $5,206 |
| Icosapent Ethyl | 28 | $4,988 |
| Metoprolol Succinate | 255 | $4,189 |
| Atorvastatin Calcium | 222 | $2,617 |
| Rosuvastatin Calcium | 112 | $2,219 |
| Amlodipine Besylate | 175 | $1,432 |
| Ezetimibe | 48 | $1,265 |
| Carvedilol | 111 | $1,188 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 31 | $1,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $113 | $233,043211 claims |
| Boehringer IngelheimJardiance | $192 | $42,20033 claims |
| NovartisEntresto | $173 | $39,92833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Santa Barbara
- Paul KurthSanta Barbara$6.1M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.